After many years of fenofibrate application in cardiovascular disorders and in type 2 diabetes mellitus (T2DM), it is time to consider the application of PPARα agonist(s) in AD and other neurodegenerative disorders, particularly in the cases of patients with altered lipid metabolism. This evidence concerns the gene PPARA and Alzheimer disease.